title: [Use of anti-B-cell therapy in case of antisynthetase syndrome as the severest subtype of polymyositis/dermatomyositis].
abstract: Antisynthetase syndrome encompassing a symptom complex with severe interstitial lung disease is the severest subtype of polymyositis and dermatomyositis. The characteristic feature of antisynthetase syndrome is the insufficient efficiency of traditional therapy with glucocorticosteroids and cytostatics, which determines the prognosis of the disease and the need for new therapeutic approaches to treating these patients.
authors.forename: O A
authors.initials: OA
authors.lastname: Antelava
authors.forename: A N
authors.initials: AN
authors.lastname: Khelkovskaia-Sergeeva
authors.forename: G M
authors.initials: GM
authors.lastname: Tarasova
authors.forename: N Iu
authors.initials: NIu
authors.lastname: Nikishina
authors.forename: N E
authors.initials: NE
authors.lastname: Lopatina
authors.forename: S G
authors.initials: SG
authors.lastname: Pal'shina
authors.forename: T P
authors.initials: TP
authors.lastname: Fedina
authors.forename: E G
authors.initials: EG
authors.lastname: Sazhina
mesh_terms: D058846:Antibodies, Monoclonal, Murine-Derived / Q000008:administration & dosage / Q000009:adverse effects / Q000276:immunology; D018951:Antigens, CD20 / Q000032:analysis; D064987:Cell- and Tissue-Based Therapy / Q000379:methods; D003882:Dermatomyositis / Q000150:complications* / Q000276:immunology; D016903:Drug Monitoring; D006801:Humans; D007155:Immunologic Factors / Q000008:administration & dosage / Q000009:adverse effects / Q000276:immunology; D017563:Lung Diseases, Interstitial / Q000209:etiology / Q000503:physiopathology; D015166:Monitoring, Immunologic; D009220:Myositis / Q000209:etiology / Q000276:immunology / Q000503:physiopathology / Q000628:therapy; D016032:Randomized Controlled Trials as Topic; D000069283:Rituximab; D016896:Treatment Outcome
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D018951:Antigens, CD20; D007155:Immunologic Factors; D000069283:Rituximab